Lineage Cell Therapeutics (LCTX) Misses Q4 EPS by 11c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.15), $0.11 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c